Part 01 · How it works

Mechanism.

Brenipatide activates two gut hormone receptors — GLP-1 and GIP — and is built to last, with a half-life of roughly nine to twelve days that supports a weekly injection. The reason Lilly is aiming it at the brain rather than at weight is that GLP-1 signaling appears to quiet the same reward circuits that drive cravings for food, alcohol, nicotine and opioids. Patients on GLP-1 drugs for diabetes or weight have repeatedly reported drinking less without trying, and animal studies show these receptors sit directly on the dopamine pathways that fire during reward. Brenipatide is the first drug in this class engineered from the start to test that hypothesis in dedicated addiction and psychiatric trials.

Semaglutide and tirzepatide turn down the volume on food. Brenipatide is built on the bet that the same dial turns down the volume on alcohol, cigarettes and opioids — and that one molecule can do it across addiction, depression and inflammatory disease at the same time. That is a very large bet on a mechanism that has never been tested head-on in people.

GLP-1R agonism

Activates GLP-1 receptors in the periphery and CNS. In reward circuits (VTA, nucleus accumbens), GLP-1R signaling has been shown to attenuate dopaminergic response to ethanol in preclinical models.

GIPR agonism

Co-agonism at the GIP receptor; the incremental contribution to AUD-specific endpoints is less well characterized than for metabolic endpoints.

Long-acting pharmacology

Phase 1 half-life of 9.08–12.5 days (longest at the 4.5 mg dose), giving exposure that carries past a once-weekly subcutaneous interval. Earlier descriptions of this profile as supporting once-monthly dosing were not borne out by the Phase 1 data.

Mesolimbic reward circuit

Convergent preclinical evidence that GLP-1R activation reduces ethanol self-administration and craving-like behaviors in rodents and non-human primates.

Translation uncertainty

Class observational evidence in humans is suggestive, but the leap from secondary observations with weekly metabolic agents to a dedicated neuroscience dual agonist is exactly what Phase 3 must establish — with no Phase 2 efficacy readout in AUD or depression to de-risk it.

Part 02 · Dosing & administration

How it's taken.

No validated dose

No independently validated human dosing exists for Brenipatide. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.

Dose

No validated dose

Investigational only. No approved or validated dose exists. The Phase 1 study dosed weekly at 0.3–4.5 mg with a 9–12.5 day half-life; ClinicalTrials.gov describes the Phase 3 arms only as escalating subcutaneous doses.

·

Trial-protocol only. There is no approved or validated dose, and the Phase 3 protocols do not disclose the dose or interval — ClinicalTrials.gov describes the arms only as escalating subcutaneous doses.

·

The published Phase 1 study dosed weekly at 0.3, 0.75, 1.5, 3 and 4.5 mg. Earlier reporting of a once-monthly regimen was not supported by that data.

·

With a 9–12.5 day half-life, the drug clears slowly: if a serious adverse event occurs, the response is supportive care rather than rapid washout.

Need help with reconstitution?

Use the free peptide calculator for dilution, unit conversion, and injection volume.

Open calculator

Part 03 · Safety

Side effects, rare serious events, who shouldn't.

Common

Gastrointestinal effects (nausea, vomiting, diarrhea)

Occurred at the same rate on placebo (25%) in the Phase 1 study, so the drug-attributable share is unclear. Still expected as a class effect at therapeutic doses.

25% in Phase 1

Dysesthesia (burning, tingling or numbness in the skin)

Reported by nobody on placebo. This is the clearest drug-specific signal in the first human dataset and has not been explained.

15.2% in Phase 1

Decreased appetite

Part of incretin pharmacology; clinically relevant in AUD populations who may have existing nutritional compromise.

Class-expected

Constipation

Typical of GLP-1 / GIP agents.

Class-expected

Injection-site reactions

Brenipatide-specific rates have not been published.

Not reported

Serious · rare

Pancreatitis

Class concern; AUD population already has elevated pancreatitis risk from alcohol itself.

<1% (class)

Hepatic injury

Background AUD-related liver disease complicates attribution; monitor liver enzymes.

Unknown

Thyroid C-cell tumors

Inherited black-box caution from GLP-1 class.

Rodent signal

Severe GI / gastroparesis

Emerging class signal. Phase 1 GI rates matched placebo, but that was short-term dosing in volunteers.

Class-expected

Alcohol co-exposure effects

Trial population continues to drink; interaction between heavy alcohol use and peak incretin exposure is a genuinely new safety territory.

Unknown

Absolute · do not use

×

Personal or family history of medullary thyroid carcinoma (class caution inherited from GLP-1 agents)

×

Multiple endocrine neoplasia syndrome type 2 (MEN2) (class caution)

×

Known hypersensitivity to brenipatide or any component

×

History of pancreatitis

×

Pregnancy or breastfeeding

×

Severe gastrointestinal disease (gastroparesis)

×

Use outside of a registered clinical trial (brenipatide is not approved; there is no legitimate supply chain)

Relative · discuss first

!

Severe alcohol-related liver disease (decompensated cirrhosis) — trial exclusions likely apply

!

History of pancreatitis — already a class caution, compounded by AUD-related pancreatic risk

!

Active use of naltrexone, acamprosate, or disulfiram — typically excluded in trials

!

Pregnancy or breastfeeding

!

Severe gastrointestinal disease (gastroparesis)

!

Any attempt to source brenipatide outside of the Lilly trial — no legitimate supply chain exists

Interactions

Alcohol

The target population continues to consume alcohol during the trial. GI side effects of incretin agents may be magnified by concurrent heavy alcohol use; hepatic injury risk may compound.

Major

Naltrexone, acamprosate, disulfiram

Concurrent AUD pharmacotherapy is typically excluded in trials; combined use outside of research has no established safety or efficacy basis

Unknown

Insulin and sulfonylureas

As with other incretin agents, expected additive hypoglycemia risk in any patient with co-existing diabetes

Major

Oral medications with narrow therapeutic index (warfarin, digoxin, levothyroxine)

Delayed gastric emptying (incretin class effect) may alter oral drug absorption; monitor levels appropriately

Moderate

Oral hormonal contraceptives

Delayed gastric emptying may reduce absorption; non-oral contraception may be preferable during trial participation.

Moderate

Labs to monitor

Liver panel (AST, ALT, GGT)

Baseline and every 3 months per trial protocol

AUD-related hepatic injury is common; monitor baseline and during treatment

CBC with Differential

Baseline and every 6 months

Screen for alcohol-associated macrocytosis and thrombocytopenia

CMP (Comprehensive Metabolic Panel)

Baseline and every 3 months

Renal function, electrolytes, and incretin-class hepatic/renal monitoring

Lipase

Baseline and if symptomatic

Pancreatitis surveillance (incretin class concern)

Phosphatidylethanol (PEth) or other alcohol biomarker

Per trial protocol

Objective measure of alcohol use alongside self-report

HbA1c and Fasting Glucose

Baseline and every 6 months

Incretin-class glycemic tracking; AUD is associated with metabolic dysregulation

Part 04 · Evidence

How strong is the evidence?

52

Grade D

Grade D reflects the state of public evidence, not the quality of the science. Mechanistic plausibility is solid; the class signal is real and consistent. What is missing is any brenipatide-specific efficacy data — the only human results released are Phase 1 safety and pharmacokinetics, in a conference poster. The Phase 3 readouts will move this score substantially in either direction.

Mechanistic plausibility

GLP-1 signaling in addiction reward circuits is well-mapped preclinically; GIP's contribution is less clear.

78

Animal data

Rodent GLP-1 / ethanol work is robust and independently replicated; brenipatide-specific preclinical data not in the public domain.

74

Human trial quality

Phase 3 in progress. A Phase 1 safety/PK dataset was presented as a conference poster in September 2026; no peer-reviewed brenipatide efficacy data exists in any indication.

42

Replication

Zero brenipatide-specific human replication; class-evidence replication exists only for GLP-1-alone agents in secondary AUD endpoints.

30

Safety signal

Phase 1 showed no serious adverse events and GI rates matching placebo, but dysesthesia in 15.2% vs 0% is an unexplained drug-specific signal. Long-term exposure in the AUD population remains unknown territory.

55

Long-term data

No multi-year data on brenipatide in any population. AUD is a chronic condition — multi-year evidence is what will matter.

32

Part 05 · Research log

Every study we cite.

We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.

01

2026

Psych Congress 2026 poster (Goldsmith P, Garhyan P, Yan S, et al.) — study J2S-MC-GZMD Preliminary

Phase 1 multiple-ascending-dose study of brenipatide — first human safety and PK data

Half-life 9.08–12.5 days (longest at 4.5 mg); plasma concentration just over 1,000 ng/mL on Day 78 at the top dose, dose-dependent. No deaths or serious adverse events. Four participants (2.2%) discontinued for a treatment-emergent adverse event. GI effects in 25% of both brenipatide and placebo groups. Dysesthesia in 15.2% on brenipatide vs 0% on placebo. Primary endpoint was safety; no efficacy endpoints were reported.

Investigator- and participant-blind multiple ascending dose, three BMI groups, weekly SC dosing at 0.3–4.5 mg, 8-week follow-up · n = 200 · Industry-sponsored and presented as a conference poster. Press coverage framed this as 'clinical promise' in substance use and psychiatric disorders; it is a dose-selection study and says nothing about efficacy.

Low-moderate (Phase 1, not peer-reviewed)

01

2025

ClinicalTrials.gov — NCT07219966 Preliminary

RENEW-ALC-1: Phase 3 brenipatide (LY3537031) vs placebo in moderate-to-severe AUD

Recruiting since Oct 15, 2025 across 119 sites. Primary outcome: change in drinking patterns via Timeline Followback (TLFB). Secondary: PACS craving scale, AUDIT, body weight, SF-36, PK Cavg, anti-drug antibodies. Notable site PIs include Lara Ray (UCLA), Henry Kranzler (Penn), Darin Dougherty (Mass General Brigham). Primary completion April 2028.

Phase 3 multicenter double-blind RCT, escalating SC dosing, 56-week treatment · n = 1,100 · Industry-sponsored (Eli Lilly). Await peer-reviewed publication; do not rely on interim sponsor communications.

N/A pending readout

02

2025

ClinicalTrials.gov — NCT07219953 Preliminary

RENEW-ALC-2: parallel Phase 3 brenipatide trial in broader AUD population

Recruiting since Oct 16, 2025 across 114 sites. Same intervention (LY3537031) as RENEW-ALC-1 but broader eligibility criteria. Together the two trials enroll 2,200 participants — among the largest dedicated AUD pharmacotherapy programs ever run.

Companion Phase 3 RCT, same intervention, 56-week treatment · n = 1,100 · Same sponsor; two-trial design is standard for pivotal registration programs.

N/A pending readout

03

2025

Molecular Psychiatry (PMID 40931165, DOI 10.1038/s41380-025-03199-3)

Genetic support for GLP-1R and GIPR in alcohol use behaviors — drug-target Mendelian randomization

Genetic proxies for GLP-1R and GIPR activation were associated with reduced binge drinking (β = −0.44, P = 2.4×10⁻³), reduced heavy drinking with psychiatric comorbidity (OR 0.62, P = 0.003), and lower NAFLD/ALT. Individual-locus analyses supported both GIPR and GLP-1R as independently protective — the strongest causal-inference support to date for the dual-target hypothesis brenipatide is built on.

Multi-ancestry Mendelian randomization, NIAAA-led · MR uses genetic variants as lifelong-exposure proxies — not a direct pharmacology readout and not brenipatide-specific.

High (causal inference)

04

2026

EBioMedicine (PMID 41506148, DOI 10.1016/j.ebiom.2025.106119)

Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents

Dual GLP-1/GIP agonist tirzepatide attenuated alcohol's rewarding properties (locomotor stimulation, conditioned place preference, accumbal dopamine release), dose-dependently reduced voluntary intake, prevented binge and relapse-like drinking, and sustained efficacy with repeated dosing. Also induced synaptic depression in the lateral septum and altered histone regulators — suggesting a plausible neural substrate.

Rodent behavioral, electrophysiology, microdialysis, proteomics · Uses tirzepatide rather than brenipatide; class-level translation is assumed, not proven.

High (preclinical)

05

2025

Psychopharmacology (PMID 40699363, DOI 10.1007/s00213-025-06854-3)

Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in rats

Acute administration of all three incretin polyagonists attenuated alcohol's discriminative stimulus effects. Repeated semaglutide maintained efficacy across 15 days; effect reversed three days after cessation. First head-to-head preclinical comparison across GLP-1 mono-, dual-, and triple-agonist designs in an AUD-relevant paradigm.

Operant drug discrimination, male and female rats, acute and repeated dosing · Preclinical and non-brenipatide. Supports the mechanism, not the specific molecule.

High (preclinical)

06

2025

ClinicalTrials.gov — NCT06817356 Preliminary

Lilly's companion program: mazdutide Phase 2 proof-of-concept in AUD (NCT06817356)

Eli Lilly is running a parallel Phase 2 trial of mazdutide (dual GLP-1/glucagon agonist) in AUD, active-not-recruiting since Feb 2025, primary completion Aug 2026. Confirms Lilly's strategic commitment to the AUD indication across multiple incretin molecules rather than a single-molecule bet.

Phase 2, double-blind, placebo-controlled · n = 300 · Different receptor pair (GLP-1/glucagon) and different molecule — portfolio context, not direct brenipatide evidence.

N/A pending readout

07

2026

ClinicalTrials.gov — NCT07412756, NCT07775300, NCT07410507, NCT07286175, NCT07420283, NCT07223840, NCT07759245, NCT07219173, NCT07545759, NCT07545772 Preliminary

RENEW program expansion: depression, schizophrenia, bipolar, opioid use disorder, smoking, COPD, asthma, IBS

Lilly has registered brenipatide in twelve RENEW trials. RENEW-MDD-1 (NCT07412756, primary completion Feb 2028) and RENEW-MDD-2 (NCT07775300, Dec 2028) are Phase 3 in major depressive disorder, with time to relapse as the key endpoint. Phase 2 trials cover schizophrenia (n=450), bipolar disorder (n=400), opioid use disorder (n=465), smoking relapse prevention (n=222), COPD (n=606), asthma (n=531), and IBS-D and IBS-C. All are recruiting.

Two Phase 3 trials in major depressive disorder (n=1,000 each) plus eight Phase 2 trials across psychiatry, addiction, respiratory and GI indications · n = 5,047 · Registration is intent, not evidence. A program this broad across unrelated organ systems is as consistent with an exploratory platform bet as with a strong internal signal.

N/A pending readout

Part 06 · Cost & access

Where it's available, at what price.

United States

Investigational

Available only by enrolling in a Lilly trial — the Phase 3 RENEW-ALC program in alcohol use disorder (NCT07219966, NCT07219953), the Phase 3 RENEW-MDD program in depression (NCT07412756, NCT07775300), or one of the Phase 2 trials in schizophrenia, bipolar disorder, opioid use disorder, smoking relapse, COPD, asthma or IBS. Search ClinicalTrials.gov for enrolling locations near you.

No cost within a trial

United Kingdom

Investigational

Confirmed site presence in the RENEW-ALC program (including sites led by Julia Sinclair, Southampton).

No cost within a trial

Belgium · Germany

Investigational

Confirmed EU trial sites in the RENEW-ALC program.

No cost within a trial

Japan · South Korea · Taiwan · China

Investigational

Confirmed Asia-Pacific sites in the RENEW-ALC program.

No cost within a trial

Gray-market / compounded

Not available

We strongly advise against. Brenipatide is a new-entity investigational peptide. Any retail 'brenipatide' is of unverifiable origin and the AUD population is especially poorly served by unverified pharmacotherapy.

N/A

The Peptide Column takes no affiliate commission from any source. For brenipatide, the only legitimate access route is the Phase 3 trial — we will not link to any other source.

Part 07 · Your appointment

Questions to bring.

01

Is there a brenipatide trial site enrolling in my region, and am I eligible given my drinking pattern and medical history?

02

Given that brenipatide is investigational, what FDA-approved AUD medications (naltrexone, acamprosate, disulfiram) should I consider first?

03

Brenipatide stays in the body for weeks after a dose — if I have a bad reaction, what are the options besides stopping and waiting it out?

04

What behavioral treatment is expected alongside any pharmacotherapy for my AUD?

References

Every citation, numbered.

Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.

01.
Phase 1 multiple-ascending-dose study of brenipatide — first human safety and PK data · Psych Congress 2026 poster (Goldsmith P, Garhyan P, Yan S, et al.) — study J2S-MC-GZMD, 2026
01.
RENEW-ALC-1: Phase 3 brenipatide (LY3537031) vs placebo in moderate-to-severe AUD · ClinicalTrials.gov — NCT07219966, 2025
02.
RENEW-ALC-2: parallel Phase 3 brenipatide trial in broader AUD population · ClinicalTrials.gov — NCT07219953, 2025
03.
Genetic support for GLP-1R and GIPR in alcohol use behaviors — drug-target Mendelian randomization · Molecular Psychiatry (PMID 40931165, DOI 10.1038/s41380-025-03199-3), 2025
04.
Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents · EBioMedicine (PMID 41506148, DOI 10.1016/j.ebiom.2025.106119), 2026
05.
Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in rats · Psychopharmacology (PMID 40699363, DOI 10.1007/s00213-025-06854-3), 2025
06.
Lilly's companion program: mazdutide Phase 2 proof-of-concept in AUD (NCT06817356) · ClinicalTrials.gov — NCT06817356, 2025
07.
RENEW program expansion: depression, schizophrenia, bipolar, opioid use disorder, smoking, COPD, asthma, IBS · ClinicalTrials.gov — NCT07412756, NCT07775300, NCT07410507, NCT07286175, NCT07420283, NCT07223840, NCT07759245, NCT07219173, NCT07545759, NCT07545772, 2026
09.
Goldsmith P, Garhyan P, Yan S, et al. — Psych Congress 2026 poster (Sept 15–19, New Orleans). Phase 1 clinical data supporting dose selection — the only human brenipatide data in the public domain
10.
GEN — 'Lilly's GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders' (Oct 7, 2026). Trade coverage of the Phase 1 poster and Phase 3 trial designs
11.
ClinicalTrials.gov — NCT07219966 (RENEW-ALC-1) and NCT07219953 (RENEW-ALC-2). Phase 3 brenipatide in alcohol use disorder — primary public source
12.
ClinicalTrials.gov — NCT07412756 (RENEW-MDD-1) and NCT07775300 (RENEW-MDD-2). Phase 3 brenipatide in major depressive disorder
13.
ClinicalTrials.gov — NCT07410507, NCT07286175, NCT07420283, NCT07223840, NCT07759245, NCT07219173, NCT07545759, NCT07545772. Phase 2 program: schizophrenia, bipolar, opioid use disorder, smoking relapse, COPD, asthma, IBS-D and IBS-C
14.
ClinicalTrials.gov — NCT07476118. Phase 1 brenipatide in healthy participants with overweight or obesity
15.
ClinicalTrials.gov — NCT06817356. Lilly's Phase 2 mazdutide-in-AUD companion program (portfolio context)
16.
Reitz et al., Mol Psychiatry 2025 (PMID 40931165). Multi-ancestry Mendelian randomization — GIPR/GLP-1R genetic support for AUD target
17.
Edvardsson et al., EBioMedicine 2026 (PMID 41506148). Tirzepatide reduces alcohol drinking and relapse in rodents
18.
Windram et al., Psychopharmacology 2025 (PMID 40699363). Incretin polyagonists attenuate alcohol's interoceptive effects in rats

Part 08 · Related

Brenipatide

Mechanism.

How it's taken.

Side effects, rare serious events, who shouldn't.

How strong is the evidence?

Every study we cite.

Where it's available, at what price.

Questions to bring.

Every citation, numbered.

Further reading.